OSR Health, Inc. (OSRH) Form 10-Q — Aug 14, 2026
OSR Health, Inc. reported Q2 2026 net sales of $315,669, down 72% from $1,135,517 a year earlier, as its RMC device-distribution unit shifted from purchase-and-resale to a consignment commission model. The change lifted gross margin to 27% from roughly 3%, cut SG&A 41%, and narrowed the quarterly net loss to $1.00 million from $5.23 million. Liquidity is the pressing issue: the company held $1.50 million in cash at June 30, 2026 after using $3.42 million of operating cash in the first half, and management cited an urgent need for additional capital.
Key figures
- Revenue
- 315669
- Net Income
- -1004038
- Total Debt
- 5428648
- Revenue Yoy
- -72
- Total Assets
- 166623360
- Cash Position
- 1499603
- Shares Outstanding
- 35118692
- Goodwill
- 29186630
- Intangibles net
- 134141267
- H1 2026 net sales
- 799727
- Q2 2025 net sales
- 1135517
- Accumulated deficit
- 40950247
- Woori io patent usd
- 6566615
- Fy2025 operating loss
- 18330000
- Woori io goodwill usd
- 6405124
- Cvr 12m shares per cvr
- 2
- Deferred legal fees usd
- 1250000
- Eloc commitment cap usd
- 78900000
- Gross margin q2 2025 pct
- 3
- Gross margin q2 2026 pct
- 27
- H1 2026 net sales yoy pct
- -58
- Q2 2026 eloc shares issued
- 1818937
- Cvr 12m price threshold usd
- 5
- Vaximm future obligation chf
- 28898
- Benjamin securities claim usd
- 425000
- Eloc shares issued cumulative
- 4875440
- Cvr max bonus shares per share
- 5
- Q2 2026 operating loss yoy pct
- -42
- Shares outstanding dec 31 2025
- 26597769
- Q2 2026 eloc gross proceeds usd
- 1280000
- Spac trust funds unreleased usd
- 1200000
- Note 2026 outstanding balance usd
- 927495
- Eloc gross proceeds cumulative usd
- 3380000
- Woori io acquisition consideration usd
- 10453116
- Chardan deferred underwriting commission usd
- 2070000
- Rd expense run rate if financed per quarter usd
- 2.5M-3.0M, potentially 5.0M-6.0M
Price after filing
Close on the filing date to close N calendar days later (from $0.32). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.